Mechanistic studies have shown that Skp2 inhibition of BRAFV600E is dependent on c-Myc transcription factors by specifically binding to the E-box region on the Skp2 promoter, suggesting that targeting Skp2 might be a promising treatment in BRAF inhibitor resistant melanomas [112]. The gene discussed is SKP2; the disease is melanoma.